Alembic Pharmaceuticals Limited announced the incorporation of its Wholly Owned Subsidiary (WOS), Alvesta Pharmaceuticals FZCO, in Dubai, United Arab Emirates. Established on 1st September, 2026, this new entity aims to explore new business opportunities and promote, sell, and distribute the company’s pharmaceutical products. The incorporation represents a strategic step for Alembic’s global expansion efforts, with an initial investment of AED 100,000.
Alembic Pharmaceuticals Expands Global Footprint
Alembic Pharmaceuticals Limited has officially announced the incorporation of its new Wholly Owned Subsidiary (WOS) named Alvesta Pharmaceuticals FZCO. This strategic move establishes the company’s presence in Dubai, United Arab Emirates, with the incorporation taking place on 1st September, 2026. This development is a key step in Alembic’s ongoing efforts to broaden its international reach and operational capabilities.
Strategic Objectives of the New Entity
The newly formed entity, Alvesta Pharmaceuticals FZCO, has been established with the clear objective of exploring new business opportunities within the target market. Furthermore, it will be instrumental in promoting, selling, and distributing Alembic Pharmaceuticals’ product portfolio. This expansion is designed to enhance the company’s market penetration and revenue streams in a key international region.
Investment and Structure
The incorporation details reveal that the subsidiary, Alvesta Pharmaceuticals FZCO, has been subscribed with an initial cost of AED 100,000 (Arab Emirates Dirham One Lakh Only). This investment covers the subscription of 100 shares at AED 1,000 each. The holding company of this new entity is Alembic Global Holding SA (“AGH”), which is also a WOS of Alembic Pharmaceuticals Limited. This structure ensures a 100% control over the new subsidiary through AGH, aligning with the company’s strategic vision.
Source: BSE
